The Molecular Cytogenetics Facility (MCF) provides basic and clinical investigators with conventional and FISH-based cytogenetic services. The goals of the core are to provide 1) high-quality, reasonably-priced cytogenetic services and expertise for requesting investigators;2) standard chromosome karyotyping and G, C, Q, R, silver staining to ascertain chromosomal abnormalities for evidence of genomic instability; 3) fluorescence in situ hybridization (FISH) of metaphase spreads using commercially- available chromosome paint probes, locus-specific probes, and telomere probes;4) Spectral Karyotyping (SKY) service to unambiguously identify, in one hybridization reaction, mouse or human chromosomal translocations present within a metaphase spread;5) specialized services, such as telomere length determination by Quantitative-FISH (Q-FISH), on an as-needed basis;and 6) access to personnel who are highly-experienced in a variety of cytogenetic technologies as well as access to the methodologies themselves. The MCF avoids expensive duplication in individual faculty laboratories of personnel, facilities, and equipment required for application of these powerful tools. The Facility occupies 250 sq. ft. within the Department of Cancer Genetics. An additional 200 sq. ft. microscope room houses 4 fluorescent microscopes for chromosomal analyses. The MCF is staffed with a Director, a Co-Director, 1 Laboratory Assistant, 'and a Professor Emeritus. During the previous funding period, 741 specimens were collected for both conventional and FISH-based cytogenetic services. Peer-funded investigators are given priority for MCF services that were used by 76 investigators from 18 of the 19 CCSG programs. 92% of users had peerreviewed funding and accounted for 85% of utilization. Since its inception, the MCF has successfully supported 5 peer-reviewed NIH-funded grants and investigators using data generated by the MCF have published extensively in top-tier journals. Future plans are to establish new cytogenetic services as well as to upgrade existing technologies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-36
Application #
8310876
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
36
Fiscal Year
2011
Total Cost
$155,980
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid et al. (2018) Phase 3 results for vosaroxin/cytarabine in the subset of patients ?60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica 103:e514-e518
Assi, Rita; Kantarjian, Hagop M; Kadia, Tapan M et al. (2018) Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124:2758-2765
Yam, Clinton; Murthy, Rashmi K; Valero, Vicente et al. (2018) A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36:299-306
Lacourt, Tamara E; Vichaya, Elisabeth G; Escalante, Carmen et al. (2018) An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology 96:109-117
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10
Dang, Nam H; Ogura, Michinori; Castaigne, Sylvie et al. (2018) Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 182:583-586
Chahoud, Jad; Sui, Dawen; Erwin, William D et al. (2018) Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res 24:2304-2311

Showing the most recent 10 out of 12418 publications